is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. MT103/MEDI-538, which is the first product candidate based on Micromet's novel BiTE(R) product development platform, is being evaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkins lymphoma. The BiTE product development platform is based on a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful 'killer cells' of the human immune system. Adecatumumab (MT201), a recombinant human monoclonal antibody which targets EpCAM expressing tumors, has completed two phase 2a clinical trials, one in patients with breast cancer and the other in patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. Micromet has established collaborations with MedImmune, Inc. for MT103/MEDI-538 and Merck Serono for adecatumumab (MT201).

Forward-Looking Statements of MedImmune, Inc.

This announcement contains, in addition to historical information, certain "forward-looking statements" regarding the development of a novel BiTE(R) molecule (bscEphA2xCD3) targeting the tyrosine kinase receptor EphA2 and CEA- BiTE targeting the CEA antigen to treat certain cancers. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change and could cause actual outcomes and results to differ materially from current expectations. In addition to risks and uncertainties discussed in MedImmune's filings with the U.S. Securities and Exchange Commission, no assurance exists that development efforts for any such product will succeed, that any such product will receive required r
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
2. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
3. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
4. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
5. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
6. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
7. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
8. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
9. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
10. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
11. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR